Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: The GIPS-III randomized clinical trial

Chris P. H. Lexis, Iwan C. C. van der Horst*, Erik Lipsic, Wouter G. Wieringa, Rudolf A. de Boer, Ad F. M. van den Heuvel, Hindrik W. van der Werf, Remco A. J. Schurer, Gabija Pundziute, Eng S. Tan, Wybe Nieuwland, Hendrik M. Willemsen, Bernard Dorhout, Barbara H. W. Molmans, Anouk N. A. van der Horst-Schrivers, Bruce H. R. Wolffenbuttel, Gert J. ter Horst, Albert C. van Rossum, Jan G. P. Tijssen, Hans L. HillegeBart J. G. L. de Smet, Pim van der Harst, Dirk J. van Veldhuisen, GIPS-III Investigators

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

111 Citaten (Scopus)

Samenvatting

IMPORTANCE Metformin treatment is associated with improved outcome after myocardial infarction in patients with diabetes. In animal experimental studies metformin preserves left ventricular function.

OBJECTIVE To evaluate the effect of metformin treatment on preservation of left ventricular function in patients without diabetes presenting with ST-segment elevation myocardial infarction (STEMI).

DESIGN, SETTING, AND PARTICIPANTS Double-blind, placebo-controlled study conducted among 380 patients who underwent primary percutaneous coronary intervention (PCI) for STEMI at the University Medical Center Groningen, the Netherlands, between January 1, 2011, and May 26, 2013.

INTERVENTIONS Metformin hydrochloride (500 mg) (n = 191) or placebo (n = 189) twice daily for 4 months.

MAIN OUTCOMES AND MEASURES The primary efficacy measure was left ventricular ejection fraction (LVEF) after 4 months, assessed by magnetic resonance imaging. A secondary efficacy measure was the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration after 4 months. The incidence of major adverse cardiac events (MACE; the combined end point of death, reinfarction, or target-lesion revascularization) was recorded until 4 months as a secondary efficacy measure.

RESULTS At 4 months, all patients were alive and none were lost to follow-up. LVEF was 53.1%(95% CI, 51.6%-54.6%) in the metformin group (n = 135), compared with 54.8%(95% CI, 53.5%-56.1%) (P = .10) in the placebo group (n = 136). NT-proBNP concentration was 167 ng/L in the metformin group (interquartile range [IQR], 65-393 ng/L) and 167 ng/L in the placebo group (IQR, 74-383 ng/L) (P = .66). MACE were observed in 6 patients (3.1%) in the metformin group and in 2 patients (1.1%) in the placebo group (P = .16). Creatinine concentration (79 mu mol/L [IQR, 70-87 mu mol/L] vs 79 mu mol/L [IQR, 72-89 mu mol/L], P = .61) and glycated hemoglobin (5.9% [IQR, 5.6%-6.1%] vs 5.9% [IQR, 5.7%-6.1%], P = .15) were not significantly different between both groups. No cases of lactic acidosis were observed.

CONCLUSIONS AND RELEVANCE Among patients without diabetes presenting with STEMI and undergoing primary PCI, the use of metformin compared with placebo did not result in improved LVEF after 4 months. The present findings do not support the use of metformin in this setting.

Originele taal-2English
Pagina's (van-tot)1526-1535
Aantal pagina's10
TijdschriftJAMA - Journal of the American Medical Association
Volume311
Nummer van het tijdschrift15
DOI's
StatusPublished - 16-apr-2014

Citeer dit